N-[2-(4-羟基苯基)乙基]-2-苯基乙酰胺 | 176039-99-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[2-(4-羟基苯基)乙基]-2-苯基乙酰胺
• 英文名称: 4-<2-(benzylcarbonylamino)ethyl>phenol
• 英文别名: N-[2-(4-hydroxyphenyl)ethyl]-2-phenylacetamide；N-(4-hydroxyphenethyl)-2-phenylacetamide；phenylacetyltyramine；Benzeneacetamide, N-[2-(4-hydroxyphenyl)ethyl]-
• CAS: 176039-99-9
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: LRKMKJMUWJYINS-UHFFFAOYSA-N

物化性质

• 沸点：
  521.0±43.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(4-羟基苯基)乙基]-2-苯基乙酰胺 在 N-碘代丁二酰亚胺 、 三氟甲磺酸 、 4 A molecular sieve 、 potassium tert-butylate 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  Iodonium ion-assisted synthesis of a tetrameric fragment corresponding to the cell wall phenolic glycolipids of Mycobacterium kansasii serovar I

  摘要：

  Two procedures are described towards the assembly of the tyramine spacer-containing tetramer 5, a derivative of the phenolic glycolipid of Mycobacterium kansasii serovar I. First, iodonium ion-mediated glycosylation of trimeric acceptor 2a with D-rhamnopyranoside donor 10 gave fully protected tetramer 17. Selective removal of the chloroacetyl group of 17, subsequent deoxygenation and removal of the protective groups, led to target 5. The potential occurrence of double stereodifferentiation (DSD) was examined by condensation of L-fucopyranoside model acceptor 14 with both the enantiomeric rhamnopyranoside donors 10 and 13. The second procedure involves elongation of trimeric acceptor 2b with 6-deoxy-D-glucopyranoside 28. Desulfurisation of the resulting tetrameric fragment 36 followed by hydrogenation of 37 gave 38, the phenylacetyl (PhAc) of which was enzymatically removed to yield target tetramer 5.

  DOI：

  10.1016/0040-4020(96)00035-x
• 作为产物：
  描述：

  苯乙酸 在 氯化亚砜 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 N-[2-(4-羟基苯基)乙基]-2-苯基乙酰胺
  参考文献：
  名称：

  含CF键作为甾族硫酸酯酶抑制剂的N-酰化酪胺氨基磺酸盐的合成和生物学评估。

  摘要：

  甾族硫酸酯酶（STS）负责将无生物活性的硫酸化类固醇水解为活性的未硫酸化形式，并促进各种激素依赖性癌症（例如乳腺癌）的生长。因此，STS酶是治疗类固醇敏感性癌症的有前途的治疗靶标。在这里，我们报告了基于潜在的STS抑制剂的氨基磺酸类似物的合成和生物学评估，该抑制剂基于含有CF键的N-酰化酪胺。使用从人胎盘分离的STS测试类似物的抑制作用。在测试的类似物中，4-（2-全氟十一烷酰氨基乙基）-氨基磺酸苯酯表现出最大的抑制作用，IC50值为2.18μM（香豆素-7-O-氨基磺酸盐的IC50值为2.13μM ）。这些发现得到了我们使用分子对接技术进行的计算分析结果的支持。本文受版权保护。版权所有。

  DOI：

  10.1111/cbdd.12931

文献信息

• [EN] BORONIC ACID CATALYSTS AND METHODS OF USE THEREOF FOR ACTIVATION AND TRANSFORMATION OF CARBOXYLIC ACIDS<br/>[FR] CATALYSEURS À BASE D'ACIDE BORONIQUE ET PROCÉDÉS D'UTILISATION ASSOCIÉS POUR L'ACTIVATION ET LA TRANSFORMATION D'ACIDES CARBOXYLIQUES
  申请人：UNIV ALBERTA

  公开号：WO2012109749A1

  公开（公告）日：2012-08-23

  The present application provides methods and catalysts for activation of carboxylic acids for organic reactions. In particular, methods are disclosed for direct nucleophilic addition reactions, such as, amidation reactions with amines, cycloadditions, and conjugate additions, using boronic acid catalysts of formula I, II or III: Also included are novel boronic acid catalysts of formula IV, V and III:

  本申请提供了用于活化羧酸进行有机反应的方法和催化剂。具体而言，揭示了用于直接亲核加成反应的方法，例如与胺的酰胺化反应，环加成和共轭加成，使用式I、II或III的硼酸催化剂：还包括式IV、V和III的新型硼酸催化剂：
• Direct Amidation of Carboxylic Acids Catalyzed by <i>ortho</i>-Iodo Arylboronic Acids: Catalyst Optimization, Scope, and Preliminary Mechanistic Study Supporting a Peculiar Halogen Acceleration Effect
  作者：Nicolas Gernigon、Raed M. Al-Zoubi、Dennis G. Hall

  DOI：10.1021/jo3013258

  日期：2012.10.5

  synthetic products motivates the development of catalytic, direct amidation methods employing free carboxylic acids and amines that circumvent the need for stoichiometric activation or coupling reagents. ortho-Iodophenylboronic acid 4a has recently been shown to catalyze direct amidation reactions at room temperature in the presence of 4A molecular sieves as dehydrating agent. Herein, the arene core of ortho-iodoarylboronic

  酰胺作为生物分子和合成产物的组成部分的重要性促使人们开发使用游离羧酸和胺的催化，直接酰胺化方法，从而避免了对化学计量活化或偶合试剂的需求。最近已显示，在存在作为脱水剂的4A分子筛的情况下，邻-碘苯基硼酸4a在室温下催化直接酰胺化反应。在这里，邻域的芳烃核心关于环取代的电子效应，已经优化了-碘芳基硼酸催化剂。与预期相反，发现给电子取代基是优选的，特别是在碘化物对位的烷氧基取代基。最佳新催化剂5-甲氧基-2-碘苯基硼酸（MIBA，4f）在动力学上比母体去甲氧基催化剂4a具有更高的活性，在温和条件下于室温下以较短的反应时间提供了更高的酰胺产物收率。温度。催化剂4f可被回收利用并促进由脂肪族羧酸和胺，杂芳族羧酸和其他含有游离酚，吲哚和吡啶等部分的官能化底物形成酰胺。机理研究证明了分子筛在这种复杂的酰胺化过程中的重要作用。底物化学计量，浓度和催化剂阶数的测量结果导致了基于假定的酰基硼酸酯中间体的可能
• Boronic Acid Catalysts and Methods of Use Thereof for Activation and Transformation of Carboxylic Acids
  申请人：Hall Dennis

  公开号：US20140142322A1

  公开（公告）日：2014-05-22

  The present application provides methods and catalysts for activation of carboxylic acids for organic reactions. In particular, methods are disclosed for direct nucleophilic addition reactions, such as, amidation reactions with amines, cycloadditions, and conjugate additions, using boronic acid catalysts of formula I, II or III: Also included are novel boronic acid catalysts of formula IV, V and III:

  本申请提供了激活羧酸进行有机反应的方法和催化剂。具体而言，揭示了使用式I、II或III的硼酸催化剂进行直接亲核加成反应的方法，例如与胺的酰胺化反应、环加成反应和共轭加成反应。还包括式IV、V和III的新型硼酸催化剂。
• Reactive deep eutectic solvents for EDC-mediated amide synthesis
  作者：Debora Procopio、Carlo Siciliano、Maria Luisa Di Gioia

  DOI：10.1039/d3ob01673k

  日期：2024.2.14

  this transformation still remains a contemporary challenge. Herein, we report a greener approach for amide synthesis by using Reactive Deep Eutectic Solvents (RDESs) acting as both the reaction medium and reactants. The procedure not only avoids the use of hazardous solvents but also provides operationally simple product recovery with high purity and efficiency, without chromatographic purification

  酰胺键形成的可持续性是制药行业中始终存在的话题，因为它代表了许多临床批准药物的共同主题。尽管已经开发了许多完成环保酰胺合成的程序，但这种转变仍然是当代的挑战。在此，我们报告了一种更环保的酰胺合成方法，使用反应性低共熔溶剂（RDES）作为反应介质和反应物。该程序不仅避免了危险溶剂的使用，而且提供了操作简单、纯度高、效率高的产品回收，无需色谱纯化。该方法有效地应用于生产阿替洛尔等活性药物成分的关键中间体的合成。将克级工艺的绿色指标与传统工业策略进行比较，表明酰胺合成的绿色化取得了进步。
• Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest
  作者：Robin S. Dothager、Karson S. Putt、Brittany J. Allen、Benjamin J. Leslie、Vitaliy Nesterenko、Paul J. Hergenrother

  DOI：10.1021/ja042913p

  日期：2005.6.1

  Late-stage malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The average survival time for patients with such a diagnosis is 6 months. In general, the vast majority of anticancer drugs operate through induction of cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis (M) phase of the cell cycle. Unfortunately, the same mechanisms that melanocytes possess to protect cells from DNA damage often confer resistance to drugs that derive their toxicity from S or M phase arrest. Described herein is the synthesis of a combinatorial library of potential proapoptotic agents and the subsequent identification of a class of small molecules (triphenyl methylamides, TPMAs) that arrest the growth of melanoma cells in the G1 phase of the cell cycle. Several of these TPMAs are quite potent inducers of apoptotic death in melanoma cell lines (IC50 similar to 0.5 mu M), and importantly, some TPMAs are comparatively nontoxic to normal cells isolated from the bone marrow of healthy donors. Furthermore, the TPMAs were found to dramatically reduce the level of active nuclear factor kappa-B (NF kappa B) in the cell; NF kappa B is known to be constitutively active in melanoma, and this activity is critical for the proliferation of melanoma cells and their evasion of apoptosis. Compounds that reduce the level of NF kappa B and arrest cells in the G1 phase of the cell cycle can provide insights into the biology of melanoma and may be effective antimelanoma agents.